A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
02
06
2021
accepted:
25
08
2021
pubmed:
19
9
2021
medline:
9
3
2022
entrez:
18
9
2021
Statut:
ppublish
Résumé
Heart failure (HF) is an impactful complication of type 2 diabetes mellitus (T2DM). We aimed to develop and validate a risk score for hospitalization for HF (HHF) incorporating biomarkers and clinical factor(s) in patients with T2DM. We derived a risk score for HHF using clinical data, high-sensitivity troponin T (hsTnT), and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) from 6,106 placebo-treated patients with T2DM in SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53). Candidate variables were assessed using Cox regression. The strongest indicators of HHF risk were included in the score using integer weights. The score was externally validated in 7,251 placebo-treated patients in DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis in Myocardial Infarction 58). The effect of dapagliflozin on HHF was assessed by risk category in DECLARE-TIMI 58. The strongest indicators of HHF risk were NT-proBNP, prior HF, and hsTnT (each We developed and validated a risk score for HHF in T2DM that incorporated NT-proBNP, prior HF, and hsTnT. The risk score identifies patients at higher risk of HHF who derive greater absolute benefit from dapagliflozin.
Identifiants
pubmed: 34535469
pii: dc21-1170
doi: 10.2337/dc21-1170
pmc: PMC8546278
doi:
Substances chimiques
Biomarkers
0
Banques de données
figshare
['10.2337/figshare.16451109']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2573-2581Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002541
Pays : United States
Informations de copyright
© 2021 by the American Diabetes Association.
Références
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Circulation. 2002 May 21;105(20):2392-7
pubmed: 12021226
Lancet Diabetes Endocrinol. 2016 Sep;4(9):789-798
pubmed: 27185609
Circulation. 2019 Nov 5;140(19):1569-1577
pubmed: 31474116
N Engl J Med. 2009 Dec 24;361(26):2538-47
pubmed: 19940289
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Card Fail. 2021 Mar 1;:
pubmed: 33663906
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
Circ Res. 2016 May 27;118(11):1830-43
pubmed: 27230644
Lancet Diabetes Endocrinol. 2014 Oct;2(10):843-51
pubmed: 24731668
Am J Cardiol. 2005 Dec 1;96(11):1530-6
pubmed: 16310435
JACC Heart Fail. 2016 Jul;4(7):600-602
pubmed: 27289402
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
Diabetes Care. 2004 Mar;27(3):699-703
pubmed: 14988288
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Eur J Heart Fail. 2021 Jun;23(6):1026-1036
pubmed: 33269486
JAMA Cardiol. 2016 Dec 01;1(9):989-998
pubmed: 27681000
JACC Heart Fail. 2013 Feb;1(1):1-20
pubmed: 24621794
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Circulation. 2014 Oct 28;130(18):1579-88
pubmed: 25189213
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
N Engl J Med. 2004 Feb 12;350(7):655-63
pubmed: 14960742
J Am Coll Cardiol. 2007 Jul 17;50(3):205-14
pubmed: 17631211
Lancet. 1998 Jan 3;351(9095):9-13
pubmed: 9433422
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
N Engl J Med. 2002 Jul 18;347(3):161-7
pubmed: 12124404
Eur Heart J. 2008 Sep;29(18):2259-64
pubmed: 18650200
Prog Cardiovasc Dis. 2019 Jul - Aug;62(4):298-302
pubmed: 31377223
Circulation. 2018 Jan 16;137(3):286-297
pubmed: 29335288
N Engl J Med. 2001 Oct 4;345(14):1014-21
pubmed: 11586953